Do analysts recommend THAR or SKYE?

Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has higher valuation & earnings, THAR or SKYE?

Tharimmune is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is THAR or SKYE more profitable?

Skye Bioscience's return on equity of -217.27% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Skye Bioscience N/A -217.27% -162.39%

Which has better valuation and earnings, SKYE or PEPG?

PepGen is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is SKYE or PEPG more profitable?

PepGen's return on equity of -59.89% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% PepGen N/A -59.89% -49.62%

Which has stronger earnings & valuation, SKYE or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is SKYE or BMEA more profitable?

Skye Bioscience's return on equity of -217.27% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Biomea Fusion N/A -265.37% -103.96%

Skye Bioscience (SKYE) Competitors

$0.75 -0.02 (-2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 0.00 (-0.39%)

As of 07:57 PM Eastern

Compare

SKYE vs. THAR, PEPG, VRCA, CRDF, and BMEA

Should you buy Skye Bioscience stock or one of its competitors? MarketBeat compares Skye Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Skye Bioscience include Tharimmune (THAR), PepGen (PEPG), Verrica Pharmaceuticals (VRCA), Cardiff Oncology (CRDF), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Skye Bioscience compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skye Bioscience had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for Tharimmune. Skye Bioscience's average media sentiment score of 1.87 beat Tharimmune's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Skye Bioscience	Very Positive

Skye Bioscience's return on equity of -217.27% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Skye Bioscience	N/A	-217.27%	-162.39%

Tharimmune is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, indicating that its stock price is 195% more volatile than the broader market.

Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Skye Bioscience beats Tharimmune on 12 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to PepGen?

Skye Bioscience (NASDAQ:SKYE) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Skye Bioscience currently has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. PepGen has a consensus price target of $11.60, indicating a potential upside of 740.58%. Given Skye Bioscience's higher possible upside, equities research analysts clearly believe Skye Bioscience is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, PepGen had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for PepGen and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.87 beat PepGen's score of 0.63 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Very Positive
PepGen	Positive

PepGen's return on equity of -59.89% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
PepGen	N/A	-59.89%	-49.62%

PepGen is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Skye Bioscience has a beta of 2.95, suggesting that its share price is 195% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Summary

Skye Bioscience beats PepGen on 8 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Skye Bioscience (NASDAQ:SKYE) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Skye Bioscience has a beta of 2.95, suggesting that its stock price is 195% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Skye Bioscience has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Skye Bioscience's return on equity of -217.27% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals has higher revenue and earnings than Skye Bioscience. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Verrica Pharmaceuticals	$35.58M	2.96	-$17.89M	-$1.03	N/A

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.87 beat Verrica Pharmaceuticals' score of 0.63 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Very Positive
Verrica Pharmaceuticals	Positive

Skye Bioscience presently has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 136.93%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Skye Bioscience beats Verrica Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Skye Bioscience compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Skye Bioscience has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Skye Bioscience	N/A	-217.27%	-162.39%

Cardiff Oncology currently has a consensus price target of $8.75, indicating a potential upside of 471.90%. Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.95, meaning that its stock price is 195% more volatile than the broader market.

Cardiff Oncology has higher revenue and earnings than Skye Bioscience. Cardiff Oncology is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	177.30	-$45.85M	-$0.67	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

In the previous week, Cardiff Oncology had 3 more articles in the media than Skye Bioscience. MarketBeat recorded 4 mentions for Cardiff Oncology and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.87 beat Cardiff Oncology's score of -0.12 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiff Oncology	Neutral
Skye Bioscience	Very Positive

Summary

Cardiff Oncology and Skye Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

How does Skye Bioscience compare to Biomea Fusion?

Skye Bioscience (NASDAQ:SKYE) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Biomea Fusion is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Skye Bioscience presently has a consensus price target of $9.80, indicating a potential upside of 1,205.10%. Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 648.90%. Given Skye Bioscience's higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Skye Bioscience's return on equity of -217.27% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Biomea Fusion	N/A	-265.37%	-103.96%

Skye Bioscience has a beta of 2.95, indicating that its share price is 195% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Biomea Fusion had 4 more articles in the media than Skye Bioscience. MarketBeat recorded 5 mentions for Biomea Fusion and 1 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.87 beat Biomea Fusion's score of 0.78 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Very Positive
Biomea Fusion	Positive

Summary

Skye Bioscience and Biomea Fusion tied by winning 7 of the 14 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.06M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.52	18.68	24.75	23.76
Price / Sales	N/A	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	1.21	8.06	10.47	6.72
Net Income	-$55.92M	$23.83M	$3.56B	$337.35M
7 Day Performance	5.20%	-2.82%	-1.11%	-2.54%
1 Month Performance	-12.96%	2.22%	1.28%	1.42%
1 Year Performance	-68.01%	37.70%	21.20%	24.71%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	2.6625 of 5 stars	$0.75 -2.5%	$9.80 +1,205.1%	-68.4%	$27.06M	N/A	N/A	11	Positive News
THAR Tharimmune	N/A	$2.81 -9.5%	N/A	+52.3%	$105.83M	N/A	N/A	2	Gap Up
PEPG PepGen	2.7834 of 5 stars	$1.45 -1.4%	$11.60 +700.0%	-10.0%	$101.68M	N/A	N/A	30	Analyst Upgrade
VRCA Verrica Pharmaceuticals	3.1158 of 5 stars	$5.79 -1.9%	$14.50 +150.4%	-2.1%	$101.36M	$35.58M	N/A	40
CRDF Cardiff Oncology	1.7183 of 5 stars	$1.51 +2.0%	$10.10 +568.9%	-61.3%	$101.19M	$590K	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. THAR, PEPG, VRCA, CRDF, and BMEA

How does Skye Bioscience compare to Tharimmune?

Summary

How does Skye Bioscience compare to PepGen?

Summary

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Summary

How does Skye Bioscience compare to Cardiff Oncology?

Summary

How does Skye Bioscience compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. THAR, PEPG, VRCA, CRDF, and BMEA

How does Skye Bioscience compare to Tharimmune?

Do insiders & institutionals believe in THAR or SKYE?

Does the media favor THAR or SKYE?

Is THAR or SKYE more profitable?

Which has higher valuation & earnings, THAR or SKYE?

Which has more risk & volatility, THAR or SKYE?

Do analysts recommend THAR or SKYE?

Summary

How does Skye Bioscience compare to PepGen?

Do institutionals & insiders have more ownership in SKYE or PEPG?

Do analysts prefer SKYE or PEPG?

Does the media favor SKYE or PEPG?

Is SKYE or PEPG more profitable?

Which has better valuation and earnings, SKYE or PEPG?

Which has more risk and volatility, SKYE or PEPG?

Summary

How does Skye Bioscience compare to Verrica Pharmaceuticals?

Which has more risk & volatility, SKYE or VRCA?

Is SKYE or VRCA more profitable?

Do institutionals and insiders hold more shares of SKYE or VRCA?

Which has higher valuation and earnings, SKYE or VRCA?

Does the media favor SKYE or VRCA?

Do analysts prefer SKYE or VRCA?

Summary

How does Skye Bioscience compare to Cardiff Oncology?

Is CRDF or SKYE more profitable?

Do analysts prefer CRDF or SKYE?

Do insiders & institutionals believe in CRDF or SKYE?

Which has more volatility and risk, CRDF or SKYE?

Which has higher earnings and valuation, CRDF or SKYE?

Does the media prefer CRDF or SKYE?

Summary

How does Skye Bioscience compare to Biomea Fusion?

Which has stronger earnings & valuation, SKYE or BMEA?

Do analysts prefer SKYE or BMEA?

Is SKYE or BMEA more profitable?

Which has more volatility & risk, SKYE or BMEA?

Do institutionals & insiders believe in SKYE or BMEA?

Does the media favor SKYE or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools